Fig. 12From: Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s diseaseStructures of the acetylcholinesterase inhibitors as FDA approved Alzheimer’s disease therapeuticsBack to article page